首页 | 本学科首页   官方微博 | 高级检索  
检索        

卡培他滨间断用药治疗合并有多种慢性疾病的老年性晚期乳腺癌临床疗效分析
引用本文:高金锁.卡培他滨间断用药治疗合并有多种慢性疾病的老年性晚期乳腺癌临床疗效分析[J].中国当代医药,2012,19(2):53-54.
作者姓名:高金锁
作者单位:安徽省合肥市第三人民医院肿瘤科,安徽合肥,230022
摘    要:目的:观察卡培他滨间断用药治疗合并有多种慢性疾病的老年性乳腺癌患者的疗效及副作用。方法:26例晚期老年性乳腺癌患者,应用单药卡培他滨间断化疗。卡培他滨每日2500mg/m2,d1~14。中位化疗间隔时间为2.5个月,中位化疗周期为5个周期。结果:CR0例(0),PR3例(11.6%),SD18例(69.2%),PD5例(19.2%),1年存活率为92.3%,2年存活率为88.5%,3年存活率达76.9%。不良反应轻,主要为白细胞减少和胃肠道反应。对血糖、血压、心功能无明显影响。结论:对于合并有多种慢性疾病的老年性晚期乳腺癌,单药卡培他滨间断治疗是值得选择和进一步研究的治疗方案。

关 键 词:卡培他滨  间断化疗  老年性晚期乳腺癌  疗效分析

Clinical effect analysis of capecitabine intermittent therapy for the treatment of advanced breast carcinoma of old women associated with various chronicdiseases
Authors:GAO Jinsuo
Institution:GAO Jinsuo The Third People’s Hospital of Hefei City in Anhui Province, Hefei 230022, China
Abstract:Objective: To evaluate the efficacy and safety of capecitabine intermittent therapy for the old women with advanced breast carcinoma associated with various chronic diseases. Methods: Total 26 patients were treated with 2 500 mg/m2 of capecitabine d1-14. The median interval between chemotherapy were 2.5 months, median chemotherapy cycle were 5 cycles. Results: Complete remission was 0 case (0), the partial response were 3 cases (11.6%), stable disease were 18 cases (69.2%), progressive diesease were 5 cases (19.2%). 1-year survival rate was 92.3%, 2-year survival rate was 88.5%, 3-year survival rate was 76.9%. The mainly adverse effects included leucopenia, gastrointestinal reactions. There was no significant effect on blood glucose, blood pressure and heart function. Conclusion: To the old women with advanced breast carcinoma associated with various chronic diseases, capecitabine intermittent therapy is worthy of further study and treatment options.
Keywords:Capecitabine  Intermittent therapy  Old women with metastatic breast carcinoma  Effect analysis
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号